Skip to main content
Legend Biotech Corp logo

Legend Biotech Corp — Investor Relations & Filings

Ticker · LEGN ISIN · US52490G1022 LEI · 254900EIUFZTW136H859 US Manufacturing
Filings indexed 340 across all filing types
Latest filing 2026-05-12 Foreign Filer Report
Country KY Cayman Islands
Listing US LEGN

About Legend Biotech Corp

https://investors.legendbiotech.com/

Legend Biotech Corp. is a global, commercial-stage biotechnology company that discovers, develops, manufactures, and commercializes novel cell therapies. The company's primary focus is on treating life-threatening diseases, with a significant emphasis on oncology. Its lead product is CARVYKTI® (ciltacabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed or refractory multiple myeloma. This therapy is developed and commercialized in collaboration with Johnson & Johnson. Legend Biotech is building an end-to-end cell therapy platform to maximize patient access to its treatments and to advance its pipeline of cutting-edge cell therapy modalities for various diseases.

Recent filings

Filing Released Lang Actions
6-K - Legend Biotech Corp (0001801198) (Filer)
Foreign Filer Report
2026-05-12 English
6-K - Legend Biotech Corp (0001801198) (Filer)
Foreign Filer Report
2026-04-14 English
4 - Legend Biotech Corp (0001801198) (Issuer)
Director's Dealing
2026-03-27 English
144 - Legend Biotech Corp (0001801198) (Subject)
Regulatory Filings
2026-03-26 English
3 - Legend Biotech Corp (0001801198) (Issuer)
Director's Dealing
2026-03-19 English
3 - Legend Biotech Corp (0001801198) (Issuer)
Director's Dealing
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.